Palisade Bio registers Phase 2 trial of PALI-2108 in ulcerative colitis, recruiting begins
A newly registered Phase 2 study will test two oral doses of PALI-2108 against placebo in moderately to severely active ulcerative colitis.
Palisade Bio's activity this week centers on a single new trial registration for its lead ulcerative colitis compound.
- NCT07845487, dubbed "ASCENTRA-UC," is a Phase 2, randomized, placebo-controlled study sponsored by Palisade Bio testing PALI-2108 in participants with moderately to severely active ulcerative colitis.1 The record shows an estimated enrollment of 204 participants.1 The trial is listed as recruiting, with an actual start date of 2026-08-28.1 Participants receive either PALI-2108 at 15mg once daily, 30mg once daily, or placebo once daily.1 The primary outcome is the proportion of participants with clinical remission using the 3-component modified Mayo Score (mMS) at Week 12.1 The study is running at 115 sites in 12 countries.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.